Aura Biosciences (NASDAQ:AURA) Receives Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Aura Biosciences (NASDAQ:AURA) in a research note released on Thursday morning,Benzinga reports. HC Wainwright currently has a $22.00 price target on the stock.

A number of other research analysts have also recently commented on the company. Cowen reissued a “buy” rating on shares of Aura Biosciences in a research note on Friday, October 18th. Scotiabank increased their target price on Aura Biosciences from $20.00 to $23.00 and gave the stock a “sector outperform” rating in a research note on Friday, October 18th. Lifesci Capital raised shares of Aura Biosciences to a “strong-buy” rating in a report on Monday, September 9th. Evercore ISI upgraded Aura Biosciences to a “strong-buy” rating in a research report on Monday, September 16th. Finally, JMP Securities lifted their target price on shares of Aura Biosciences from $19.00 to $23.00 and gave the company a “market outperform” rating in a research note on Friday, September 13th. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $23.00.

Aura Biosciences Stock Down 3.8 %

NASDAQ:AURA traded down $0.38 during mid-day trading on Thursday, hitting $9.59. 199,954 shares of the company’s stock were exchanged, compared to its average volume of 175,348. Aura Biosciences has a fifty-two week low of $6.63 and a fifty-two week high of $12.38. The company has a 50 day simple moving average of $9.75 and a 200-day simple moving average of $8.50.

Aura Biosciences (NASDAQ:AURA) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.42) EPS for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.02. On average, research analysts anticipate that Aura Biosciences will post -1.7 earnings per share for the current year.

Insider Transactions at Aura Biosciences

In other news, insider Los Pinos Elisabet De sold 9,200 shares of the business’s stock in a transaction dated Tuesday, October 29th. The stock was sold at an average price of $10.74, for a total value of $98,808.00. Following the completion of the transaction, the insider now owns 320,647 shares of the company’s stock, valued at $3,443,748.78. The trade was a 2.79 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CTO Mark Plavsic sold 7,383 shares of the business’s stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $9.85, for a total transaction of $72,722.55. Following the completion of the transaction, the chief technology officer now owns 121,132 shares of the company’s stock, valued at approximately $1,193,150.20. This represents a 5.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 67,259 shares of company stock valued at $780,699. 5.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Aura Biosciences

A number of institutional investors and hedge funds have recently bought and sold shares of the business. American Century Companies Inc. bought a new stake in Aura Biosciences during the 2nd quarter worth about $119,000. American International Group Inc. increased its holdings in shares of Aura Biosciences by 27.4% in the first quarter. American International Group Inc. now owns 17,579 shares of the company’s stock worth $138,000 after acquiring an additional 3,782 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of Aura Biosciences in the 1st quarter valued at approximately $144,000. SG Americas Securities LLC acquired a new stake in Aura Biosciences during the 3rd quarter worth approximately $169,000. Finally, Rhumbline Advisers lifted its stake in Aura Biosciences by 39.6% in the second quarter. Rhumbline Advisers now owns 63,483 shares of the company’s stock valued at $480,000 after buying an additional 18,011 shares in the last quarter. Institutional investors and hedge funds own 96.75% of the company’s stock.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.